Abstract
This review deals with the results showing the relation between vitamin B12 deficiency and neurotoxicity of homocysteine and nitrite (a metabolite of nitric oxide) in Parkinsons patients treated with levodopa (L-Dopa). We have already reported a linear relationship between the CSF levels of nitrite with glutamic acid and homocysteine suggesting that the production of nitrite is interrelated with the neurotoxic level of homocysteine. The levels of nitrite and homocysteine resulting in the deficiency of vitamin B12 are some of the factors promoting degeneration in Parkinsons disease. This review emphasizes the importance of these parameters in designing suitable drug therapy for Parkinson disease. Additionally, there is evidence that increased homocysteine levels might accelerate dopaminergic cell death in Parkinson disease (PD), through neurotoxic effects. Furthermore, levodopa (L-Dopa) treatment of PD results in hyperhomocysteinemia as a consequence of L-Dopa methylation by catechol-O-methyltransferase (COMT). Therefore, higher dietary intakes of folate, vitamin B12, and vitamin B6 might decrease the risk of PD through decreasing plasma homocysteine.
Keywords: Cerebrospinal fluid, vitamin B12, homocysteine, nitrite, Parkinson's disease
CNS & Neurological Disorders - Drug Targets
Title: Is the Deficiency of Vitamin B12 Related to Oxidative Stress and Neurotoxicity in Parkinsons Patients?
Volume: 7 Issue: 1
Author(s): G. Ali Qureshi, Aftab A. Qureshi, Bika Ram Devrajani, M. A. Chippa and S. Ali Syed
Affiliation:
Keywords: Cerebrospinal fluid, vitamin B12, homocysteine, nitrite, Parkinson's disease
Abstract: This review deals with the results showing the relation between vitamin B12 deficiency and neurotoxicity of homocysteine and nitrite (a metabolite of nitric oxide) in Parkinsons patients treated with levodopa (L-Dopa). We have already reported a linear relationship between the CSF levels of nitrite with glutamic acid and homocysteine suggesting that the production of nitrite is interrelated with the neurotoxic level of homocysteine. The levels of nitrite and homocysteine resulting in the deficiency of vitamin B12 are some of the factors promoting degeneration in Parkinsons disease. This review emphasizes the importance of these parameters in designing suitable drug therapy for Parkinson disease. Additionally, there is evidence that increased homocysteine levels might accelerate dopaminergic cell death in Parkinson disease (PD), through neurotoxic effects. Furthermore, levodopa (L-Dopa) treatment of PD results in hyperhomocysteinemia as a consequence of L-Dopa methylation by catechol-O-methyltransferase (COMT). Therefore, higher dietary intakes of folate, vitamin B12, and vitamin B6 might decrease the risk of PD through decreasing plasma homocysteine.
Export Options
About this article
Cite this article as:
Qureshi Ali G., Qureshi A. Aftab, Devrajani Ram Bika, Chippa A. M. and Syed Ali S., Is the Deficiency of Vitamin B12 Related to Oxidative Stress and Neurotoxicity in Parkinsons Patients?, CNS & Neurological Disorders - Drug Targets 2008; 7 (1) . https://dx.doi.org/10.2174/187152708783885101
DOI https://dx.doi.org/10.2174/187152708783885101 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Computer-Aided Drug Design for AMP-Activated Protein Kinase Activators
Current Computer-Aided Drug Design Biology of Cholesterol Lowering in Atherosclerotic Plaques
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Smoking and Weight
Current Respiratory Medicine Reviews Non-Alcoholic Fatty Liver Disease and Vascular Disease
Current Vascular Pharmacology The Potential of Lifestyle Changes for Improving the Clinical Outcome of Patients with Coronary Heart Disease: Mechanisms of Benefit and Clinical Results
Reviews on Recent Clinical Trials Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients
Current Pharmaceutical Biotechnology Improving of Nutraceutical Features of Many Important Mediterranean Vegetables by Inoculation with a New Commercial Product
Current Pharmaceutical Biotechnology The Herpesvirus Encoded dUTPase as a Potential Chemotherapeutic Target
Current Protein & Peptide Science Incremental Value of Two Dimensional Speckle Tracking Echocardiography in the Functional Assessment and Characterization of Subclinical Left Ventricular Dysfunction
Current Cardiology Reviews Is there any Additional Prognostic Value of Central Blood Pressure Wave Forms Beyond Peripheral Blood Pressure?
Current Pharmaceutical Design Antisense Oligonucleotides for the Treatment of Dyslipidemia
Current Pharmaceutical Design Endothelial Progenitor Cells: A Vascular Perspective for Inflammatory Rheumatic Disorders
Current Rheumatology Reviews Inflammation, Atrial Fibrillation and Cardiac Surgery: Current Medical and Invasive Approaches for the Treatment of Atrial Fibrillation
Current Pharmaceutical Design Coenzyme Q10 and Neurological Diseases: An Update
Letters in Drug Design & Discovery Editorial [Hot Topic: Oxidative Stress Induced-Metabolic Imbalance, Mitochondrial Failure, And Cellular Hypoperfusion As Primary Pathogenetic Factors For The Development Of Alzheimer Disease Which Can Be Used As An Alternate And Successful Drug Treatment Strategy: Past, Present And Future (Guest Editor: Gjumrakch Aliev)]
CNS & Neurological Disorders - Drug Targets Risk and Benefit of Statins in Stroke Secondary Prevention
Current Vascular Pharmacology Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?
Current Drug Targets Neuroprotective Therapies for Alzheimers Disease
Current Pharmaceutical Design Editorial [Hot Topic: One Century of Triglycerides, but there is Still Lots to Learn(Guest Editors: K. Anagnostopoulou, D.P. Mikhailidis and G. Kolovou)]
Current Drug Targets